Pseudo-Simultaneous Imaging of Tumor Hypoxia and Proliferation in HNC Patients Using PET/CT
A Pilot Study to Assess the Feasibility of Pseudo-Simultaneous Imaging of Tumor Hypoxia and Proliferation in Head and Neck Cancer Patients Using PET/CT
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Citigroup Biomedical Imaging Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Subject Inclusion Criteria:
- Pathologic Confirmation of HNC
- No prior treatment for this diagnosis of HNC
- Patient to be treated with Radio-Therapy
- Age >= 18 years old
- Karnofsky performance status >= 70%
- Women of childbearing age must have a negative blood pregnancy test.
Exclusion Criteria:
- Women who are pregnant or breast-feeding.
- Severe diabetes (fasting blood glucose > 200- mg/dl)
- Adults who are unable to consent
- Patients who do not agree to share and store data History of lack of tolerance of the standard of care FDG-PET scan previously obtained
- History of previous intolerance of either FMISO or FLT.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Repeatability of FLT kinetics
Radiotracer: 18F-FLT Dose: 10 mCi Frequency: Two baseline PET/CT at baseline up to 3 days apart.
|
PET/CT Imaging of tumor hypoxia and proliferation
|
|
Experimental: Pseudo-Simultaneous FMISO/FLT PET/CT Imaging
Radiotracer: 18F-FLT and 18F-FLT Dose and Frequency: 8 mCi 18F-FLT and 8 mCi 18F-FLT on Day1, the 8mCi 18F-FLT on Day2
|
PET/CT Imaging of tumor hypoxia and proliferation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Simultaneous Imaging of tumor hypoxia and proliferation
Time Frame: 1 year
|
To assess the feasibility to tease out the FMISO and FLT kinetics in simultaneous FMISO/FLT PET/CT imaging.
FMISO and FLT kinetic parameters will be measured from the combined FMISO/FLT dynamic study.
The accuracy of those measurements will be tested by comparing the FLT kinetic measurements deduced from the combined FMISO/FLT study on day1 with those from the sole FLT study of day2.
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Repeatability of FLT
Time Frame: 1 year
|
To assess the repeatability of FLT kinetics.
Subjects will undergo two dynamic FLT PET studies up to 3 days apart.
The repeatability of the corresponding kinetic parameters from the two studies will be measured using statistical methods (e.g.
Bland-Altman analysis)
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Sadek Nehmeh, Ph.D., Weill Medical College of Cornell University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1703018046
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.